A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-muscle Invasive Bladder Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients who have non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype. 2) Patients who have BCG-unresponsive CIS and presence of BCG-unresponsive high-grade Ta or T1 disease.

You may not be eligible for this study if the following are true:

  • 1) Patients who have recurrence of BCG unresponsive Ta/T1 disease > 6 months after last BCG instillation or BCG unresponsive CIS > 12 months after last BCG instillation. 2) Patients who have life expectancy of less than 2 years.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.